Department of Cardiology, Changi General Hospital, Singapore.
Singapore Med J. 2020 Apr;61(4):181-183. doi: 10.11622/smedj.2019169. Epub 2019 Dec 10.
There are limitations to the sensitivity and specificity of conventional two-dimensional echocardiograms in making an accurate diagnosis in certain patient populations. This led to the development of specific contrast-enhancing agents with the following characteristics: small enough to cross the pulmonary capillary bed, remain stable throughout the length of the procedure, do not dissolve in blood, and rapidly cleared from the body with low toxicity. Unfortunately, the use of contrast echocardiography has not taken off as expected. The low take-up rate among clinicians can largely be attributed to the black box warning by the United States Food and Drug Administration in 2007, after the coincidental occurrence of four patient deaths and about 190 severe cardiopulmonary reactions shortly after contrast agent administration. In this article, we address the clinical safety of contrast agents, share our institution's experience in using it and elaborate on the clinical indications of contrast echocardiography.
在某些特定患者群体中,传统二维超声心动图在做出准确诊断方面存在局限性。这导致了具有以下特征的特定对比增强剂的发展:足够小以穿过肺毛细血管床,在整个过程中保持稳定,不会在血液中溶解,并且具有低毒性,能够迅速从体内清除。不幸的是,对比超声心动图的使用并未如预期的那样普及。临床医生的低使用率主要归因于美国食品和药物管理局在 2007 年发布的黑框警告,就在对比剂给药后不久,巧合地发生了四起患者死亡和大约 190 例严重心肺反应。在本文中,我们讨论了对比剂的临床安全性,分享了我们机构使用对比剂的经验,并详细阐述了对比超声心动图的临床适应证。